Protonix delayed-release oral suspension can be administered orally in applesauce or apple juice, or through a nasogastric tube. Protonix delayed-release oral suspension is indicated for the treatment and maintenance of healing of erosive esophagitis, with associated gastroesophageal reflux disease symptoms.
Protonix is contraindicated in patients with known hypersensitivity to any component of the formulation. Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.
Richard Lynn, senior director, global medical affairs for Wyeth Pharmaceuticals, said: “The availability of Protonix for delayed-release oral suspension provides adult patients who cannot swallow tablets with an effective and convenient way to treat their erosive gastroesophageal reflux disease.”